Tag: ProfoundBio
First Patient Dosed with PRO1184 and PRO1160 Cleared for Study Initiation...
Dosing has initiated in the Phase 1 first-in-human clinical trial of PRO1184 (NCT05579366), an antibody-drug conjugates or ADC being developed by ProfoundBio comprising a folate receptor alpha-directed antibody conjugated to the exatecan payload using a novel, proprietary hydrophilic linker.
Novel Linker-Drug Technology Enables Antibody-Drug Conjugates with an Expanded Therapeutic Window
Preclinical data from a novel, proprietary ADC technology platform being developed by ProfoundBio was being presented at the 2021 Molecular Targets and Cancer Therapeutics...
